Recombinant human deoxyribonuclease for the treatment of acute asthma in children

Ruben Boogaard, Frank Smit, Ruud Schornagel, Anja APH Vaessen-Verberne, Jan M Kouwenberg, Marion Hekkelaan, Tom Hendriks, Sander WW Feith, Wim CJ Hop, Johan C de Jongste and Peter JFM Merkus

Airway obstruction in acute asthma is the result of airway smooth muscle contraction, inflammation and mucus plugging. Case reports suggest that mucolytic therapy might bebeneficial in acute asthma. The authors aim was to determine the efficacy of the mucolyticdrug recombinant human deoxyribonuclease (rhDNase) in addition to standard treatment at the emergency department in children with an asthma exacerbation.

In a multicenter randomized double-blind controlled clinical trial, 121 children brought tothe emergency room for a moderate-to-severe asthma exacerbation were randomly assignedto receive either a single dose of 5 mg nebulized rhDNase or placebo following the second dose of bronchodilators. An asthma score (scale 5 to 15) was assessed at baseline and at1, 2, 6, 12 and 24 hours. The primary outcome variable was the asthma score 1 hour afterthe study medication.

One hour after the study medication, the asthma score in the rhDNase group showed a 1.0 (0.5 to 1.6) points adjusted mean decrease from baseline (95%CI), vs. 0.7 (0.3 to 1.2)points in the placebo group; mean difference (95% CI)= 0.4 (-0.2 to 1.0) points; P=0.23.The asthma score over the study period of 24 hours also did not significantly differbetween the rhDNase and placebo group (mean difference = 0.2 (-0.3 to 0.7) points, P=0.40).Duration of oxygen supplementation and number of bronchodilator treatments in the first 24 hours were similar in both groups. Adding a single dose of nebulized rhDNase to standard treatment in the emergency room has no beneficial effects in children with moderate to severe acute asthma.

Thorax 2007: Published online 3rd August 2007

Link to Abstract

Link to Full Text